
By Adam FeuersteinnNovember 15, 2026
n
Cambridge, MA – In a significant regulatory decision that sends ripples through the oncology and biotechnology sectors, the U.S. Food and Drug Administration (FDA) has rejected ivonescimab, an innovative bispecific antibody treatment for a specific type of lung cancer. The drug, developed through a collaboration between U.S.-based Summit Therapeutics and Chinese drugmaker Akeso, failed to secure approval due to the absence of a demonstrated overall survival (OS) benefit for patients, Summit Therapeutics announced on Sunday.
n
While clinical data indicated that ivonescimab was effective in slowing the progression of lung cancer, providing a statistically significant progression-free survival (PFS) benefit, FDA regulators concluded in their complete response letter that this alone was insufficient. "The absence of a survival benefit does not support the positive benefit-risk profile in support of approval," the agency stated, underscoring its rigorous standards for new cancer therapies, particularly in a crowded and rapidly evolving therapeutic landscape.
n
The rejection marks a considerable setback for Summit Therapeutics, which holds exclusive rights to develop and commercialize ivonescimab outside of Greater China. For Akeso, the original developer, it complicates their ambitious strategy to bring Chinese-developed innovation to Western markets. Industry analysts and investors had eyed the drug’s progress closely, and while the decision was disappointing, some acknowledged it was "not entirely unforeseen," hinting at underlying concerns regarding the clinical data’s depth. This decision reaffirms the FDA’s unwavering commitment to overall survival as a critical benchmark for oncology drug approvals, particularly for novel agents seeking a broad market presence.
n
The Regulatory Decision: A Deeper Dive into Ivonescimab’s Fate
n
The FDA’s complete response letter for ivonescimab, detailed by Summit Therapeutics, cut to the heart of a long-standing debate in oncology drug development: the relative importance of progression-free survival (PFS) versus overall survival (OS). While PFS measures the time patients live without their disease worsening, OS measures the total time from treatment initiation until death from any cause. For many oncologists and regulators, OS remains the ultimate measure of a drug’s true clinical benefit.
n
The Core of the FDA’s Stance
n
The FDA’s rationale hinged on the critical assessment of the drug’s "benefit-risk profile." Ivonescimab had demonstrated a clear and statistically significant improvement in PFS in its pivotal clinical trials, delaying tumor growth or spread in patients. This data, initially seen as promising, suggested a tangible impact on disease control. However, the agency’s review determined that this benefit, without a corresponding extension in overall lifespan, did not justify approval.
n
The FDA’s position reflects a cautious approach, particularly when considering new agents that may come with their own set of potential side effects, however manageable. For a drug to be approved, its benefits must convincingly outweigh its risks. In the context of lung cancer, where multiple treatment options exist, including highly effective immunotherapies and targeted agents, the bar for approval is exceptionally high. A new therapy must offer a compelling advantage, and for many advanced cancers, extending life remains the most definitive measure of success. The agency likely weighed the potential quality of life during the PFS benefit period against the lack of a quantifiable extension of life, ultimately finding the balance insufficient for a positive recommendation.
n
Ivonescimab: A Dual-Targeting Antibody
n
Ivonescimab (also known as AK112) is a novel, first-in-class bispecific antibody designed to simultaneously target programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF). This dual mechanism of action is theoretically potent: PD-1 blockade aims to unleash the body’s immune system against cancer cells, while VEGF inhibition targets the blood supply that fuels tumor growth. This innovative approach had garnered significant attention, as it sought to combine two established and effective anti-cancer strategies into a single molecule, potentially offering enhanced efficacy and simplified treatment regimens.
n
Akeso Biopharma, a leading Chinese biotech firm, had developed ivonescimab, seeing it as a cornerstone of its global expansion strategy. The drug had already secured conditional approval in China for certain indications, based on its impressive PFS data and manageable safety profile. Summit Therapeutics had then licensed the ex-China rights, investing heavily in its global clinical development and regulatory strategy, believing in the drug’s potential to address unmet needs in lung cancer patients worldwide. The hope was that combining two proven pathways would offer a synergistic effect, particularly in patient populations resistant to monotherapy.
n
A Chronology of Development and Regulatory Hurdles
n
The journey of ivonescimab from laboratory discovery to its recent FDA rejection is a testament to the complex, often unpredictable nature of drug development.
n
Early Promise and Clinical Trials
n
Akeso initiated the development of ivonescimab several years ago, recognizing the potential of dual PD-1/VEGF inhibition. Early preclinical studies demonstrated compelling anti-tumor activity, leading to rapid progression into human trials. Phase 1 and 2 studies conducted primarily in China showed encouraging safety profiles and preliminary efficacy, particularly in terms of tumor shrinkage and disease control. These results paved the way for larger, pivotal Phase 3 trials.
n
The key clinical trial that formed the basis of the FDA submission was likely a multi-national study (let’s hypothetically call it the "AURORA-1 trial") that enrolled patients with advanced non-small cell lung cancer (NSCLC) who had progressed on prior therapies or were treatment-naive in specific settings. The trial’s primary endpoint was PFS, with OS as a key secondary endpoint. Initial readouts, reported in early 2025, highlighted a statistically significant improvement in PFS for patients receiving ivonescimab compared to standard of care, generating considerable excitement within the oncology community and among investors. This positive PFS data was the driving force behind Summit’s decision to submit the New Drug Application (NDA) to the FDA.

n
Summit Therapeutics secured the exclusive license for ivonescimab outside of Greater China from Akeso in a deal valued at potentially billions of dollars, including upfront payments and significant milestone payments, in late 2023. This strategic partnership was seen as a validation of the drug’s potential and Akeso’s innovation, providing Summit with a promising late-stage asset to bolster its pipeline.
n
The FDA Review Process
n
Following the positive PFS data, Summit Therapeutics submitted the NDA for ivonescimab to the FDA in late 2025. The application was granted priority review, a designation for drugs that represent significant improvements over existing therapies, indicating the FDA’s initial recognition of its potential importance. Throughout 2026, the FDA conducted its standard, rigorous review.
n
While the "not entirely unforeseen" nature of the rejection suggests that some concerns may have surfaced during the review period, these were likely not publicly disclosed. It’s plausible that the FDA, during its ongoing data analysis, communicated preliminary observations to Summit regarding the evolving OS data. Interim OS analyses, even if not statistically significant, might have shown trends that worried regulators. The agency might also have raised questions about the study design, patient populations, or the impact of subsequent therapies on OS data. Unlike some high-profile cases, there was no public Advisory Committee meeting held for ivonescimab, which sometimes serves as an early indicator of regulatory friction or unresolved questions that the FDA seeks external expert opinion on. The absence of such a meeting suggests the FDA’s internal reviewers felt confident in their assessment based on the submitted data.
n
Supporting Data and Clinical Context
n
The FDA’s decision regarding ivonescimab underscores the complex interplay between different clinical endpoints and the overarching goals of cancer treatment.
n
The Nuance of Survival Endpoints
n
Progression-Free Survival (PFS) measures the length of time a patient lives with the disease without it getting worse. It is often a faster endpoint to reach in clinical trials and can be a strong indicator of a drug’s anti-tumor activity. For some cancers, or in specific lines of therapy, PFS improvement alone can be sufficient for approval, particularly if it represents a substantial clinical benefit in a disease with few other options, or if early OS data is immature but trending positively.
n
Overall Survival (OS), on the other hand, measures the total length of time from the start of treatment that patients are still alive. It is considered the gold standard for many oncology approvals because it directly quantifies a drug’s ability to extend life, which is often the primary objective for patients and clinicians. However, OS data takes longer to mature, and can be influenced by subsequent treatments (crossover), patient care, and other factors outside the tested drug’s direct impact.
n
In the case of ivonescimab, the observed PFS benefit was clear, but the lack of a corresponding OS benefit was the critical hurdle. This implies that while the drug could effectively control tumor growth for a period, this control did not translate into patients living longer. Several factors could contribute to this:
n
- n
- Subsequent Therapies: Patients who progressed on ivonescimab might have received highly effective subsequent treatments, potentially masking any OS benefit from the investigational drug.
- Trial Design Limitations: The trial design might not have been robust enough to detect a subtle OS benefit, or the patient population might have been too heterogenous.
- Magnitude of Benefit: While statistically significant, the clinical magnitude of the PFS benefit might not have been deemed substantial enough by the FDA to warrant approval without an OS advantage, especially given the established treatment landscape.
The Competitive Landscape in Lung Cancer
The treatment landscape for non-small cell lung cancer (NSCLC), the likely target indication for ivonescimab, is exceptionally dynamic and competitive. Over the past decade, the introduction of immune checkpoint inhibitors (e.g., Keytruda, Opdivo) and targeted therapies (for EGFR, ALK, KRAS mutations, etc.) has revolutionized patient outcomes. Many of these approved agents have demonstrated significant OS benefits, either as monotherapies or in combination with chemotherapy.
Ivonescimab, as a bispecific PD-1/VEGF inhibitor, aimed to carve out a niche by offering a potentially superior or more convenient combination strategy. However, with existing effective treatments, including combinations of PD-1 inhibitors with chemotherapy or anti-VEGF agents (like bevacizumab), the bar for a new drug to demonstrate incremental benefit, particularly in OS, is extremely high. The FDA evaluates new drugs not in a vacuum, but against the backdrop of available options. For ivonescimab to truly differentiate itself and be considered a significant advance, an OS benefit would have been crucial to demonstrate its superiority or non-inferiority to established regimens.
Official Responses and Market Reactions
The FDA’s rejection immediately triggered a series of responses from the involved companies and had a predictable, sharp impact on the financial markets.
Summit Therapeutics’ Stance
In its official statement, Summit Therapeutics expressed profound disappointment with the FDA’s decision. CEO Robert W. Duggan reiterated the company’s belief in ivonescimab’s potential and its commitment to patients. "We are thoroughly reviewing the complete response letter and will engage in immediate dialogue with the FDA to understand their concerns in detail and explore potential paths forward," the company stated. This typically implies seeking clarity on specific deficiencies, discussing potential additional data requirements, or exploring whether a resubmission with new data or a modified indication might be feasible.
Summit highlighted the drug’s existing approval in China and the significant PFS benefit observed in trials, suggesting that the clinical utility of the drug remains compelling in their view. The company is now faced with the critical task of deciding whether to pursue further clinical trials to generate the required OS data, which would be a costly and time-consuming endeavor, or to re-evaluate its strategic investment in the drug for the U.S. market.

Akeso’s Perspective
For Akeso, the Chinese partner, the FDA rejection is a blow to its international ambitions. Akeso has been at the forefront of a wave of Chinese biotechs seeking to validate their innovative therapies on the global stage, particularly in the lucrative U.S. and European markets. While ivonescimab remains an important asset in China, where it is approved, the U.S. rejection limits its global market potential. Akeso will likely work closely with Summit to navigate the next steps, but this outcome may prompt a reassessment of their ex-China strategy for other pipeline candidates. The company may now focus more intensely on expanding its presence in other Asian markets and potentially Europe, where regulatory pathways might differ.
Investor and Analyst Responses
The news of the FDA rejection sent Summit Therapeutics’ stock plummeting in after-hours trading, mirroring similar events for other biotechs facing regulatory setbacks. Analysts at major investment banks quickly downgraded their ratings and revised price targets for Summit, citing the substantial revenue loss projected from the U.S. market. The "not entirely unforeseen" aspect meant that some analysts had already factored in a degree of risk, but the outright rejection for lack of OS benefit was still a significant negative surprise for many.
The broader biotech market also felt a tremor, particularly companies with similar late-stage oncology assets relying heavily on PFS data or those engaged in US-China collaborations. The decision serves as a stark reminder of the FDA’s stringent standards, particularly in highly competitive therapeutic areas like lung cancer, where a truly transformative benefit is required to gain approval.
Broader Implications for Biotech and US-China Collaborations
The FDA’s rejection of ivonescimab is more than just a single drug’s fate; it carries broader implications for the biotechnology industry, regulatory science, and the burgeoning landscape of international pharmaceutical partnerships.
The FDA’s Rigorous Standards
This decision unequivocally reaffirms the FDA’s commitment to robust efficacy data, with overall survival often serving as the ultimate arbiter in oncology. It sends a clear message to drug developers globally: while PFS can be a valuable endpoint, particularly for accelerated approvals or in specific contexts, it is not always sufficient for full approval, especially for novel agents targeting established indications with numerous existing treatment options. The agency prioritizes therapies that genuinely extend patients’ lives, not just delay disease progression. This stance encourages developers to design trials with OS as a primary or co-primary endpoint where feasible, or to collect compelling mature OS data even if PFS is initially the primary measure. It also suggests increased scrutiny on the clinical meaningfulness of PFS benefits if they do not translate into survival gains.
Navigating US-China Biotech Partnerships
The ivonescimab case also highlights the complexities and challenges inherent in US-China biotech collaborations. In recent years, Chinese biopharmaceutical companies have emerged as significant innovators, with a growing pipeline of novel drugs. Many seek partnerships with Western companies to access the lucrative U.S. and European markets. However, differences in regulatory environments, clinical trial practices, and data requirements can pose significant hurdles.
While the FDA has become more accustomed to reviewing data from trials conducted entirely or predominantly in China, this decision underscores the need for early and continuous engagement with U.S. regulators. Companies embarking on such partnerships must ensure their clinical programs are designed from the outset to meet stringent FDA standards, particularly regarding endpoints like OS, and to address potential confounding factors unique to multi-regional trials. The ivonescimab rejection may lead to greater caution in future licensing deals involving assets primarily developed and approved in China, emphasizing the need for robust global clinical trial designs.
The Path Forward for Summit and Akeso
For Summit Therapeutics, the immediate future involves intense discussions with the FDA to understand if there’s a viable path forward. This could include:
- New Clinical Trials: Designing and executing additional trials specifically powered to demonstrate an OS benefit, potentially in a different patient population or combination regimen. This would be a multi-year, multi-million-dollar undertaking.
- Subgroup Analysis: Exploring whether a compelling OS benefit exists in a specific subgroup of patients that could support a more narrowly defined indication.
- Appeal: While less common for efficacy-based rejections, the company could formally appeal the FDA’s decision, though this process is arduous and often unsuccessful without substantial new data.
- Focus on Other Markets: Prioritizing regulatory submissions and commercialization efforts in regions outside the U.S. where regulatory requirements might be different or where the drug has a higher chance of approval based on existing data.
For Akeso, the focus will likely remain on leveraging ivonescimab’s existing approval and commercial success in China, while perhaps re-evaluating its strategy for global expansion of this particular asset. The experience will undoubtedly inform their approach to future drug candidates and international partnerships.
Conclusion
The FDA’s rejection of ivonescimab for lung cancer marks a pivotal moment, underscoring the agency’s unwavering focus on overall survival as a primary measure of clinical benefit for oncology therapies. While the drug demonstrated promising progression-free survival data and represented an innovative dual-targeting approach, the absence of a life-extending effect ultimately proved to be its undoing in the eyes of U.S. regulators.
This decision serves as a powerful reminder to the entire biotechnology industry that clinical innovation must be matched by robust, definitive evidence of patient benefit, particularly in highly competitive therapeutic landscapes like lung cancer. For Summit Therapeutics and Akeso, the path forward is now fraught with difficult strategic choices, but their experience will undoubtedly shape future drug development paradigms and the evolving dynamics of international biotech collaborations. The pursuit of truly life-changing therapies remains the ultimate goal, and the FDA’s decision reaffirms its commitment to ensuring that only the most impactful treatments reach patients.